Patient Fee Caps for Affordable Parkinson Assessment: Uncertainty, Subsidy Design, and Household Financial Protection

Abstract A low initial assessment charge does not guarantee an affordable clinical pathway when additional visits, interpretation, travel, or assistance generate uncertain payments. This article examines patient fee caps as one possible financing mechanism for accessible Parkinson assessment. Targeted narrative evidence on patient expenditure, digital participation, remote care, and economic evaluation informs a transparent analytical model. The model separates clinical resource costs, patient charges, external financing, and nonmedical cash expenses. Fully hypothetical scenarios demonstrate how capping a payment changes its distribution without automatically reducing the resources required for care. With three illustrative episode types, mean patient charges fall from 30 to 14 abstract cost units under a clinical-fee cap of 20, while the corresponding external-financing requirement rises from 25.5 to 41.5 units per episode. A separate cash-constraint calculation shows why protection depends on household resources and which expenses the cap covers. In the chosen example, including travel and assistance reduces the fraction of episodes within available household cash from 90% to 58.5% under the same clinical-fee cap. These are accounting and feasibility illustrations, not observed prices, uptake estimates, or measured project savings. The contribution is a framework for specifying the protected episode, payment timing, covered expenses, financing source, and clinical completion endpoint together. NeuralCipher's affordability objective is framed as reducing direct patient charges and associated household burdens, especially for people with limited financial resources. Testing that objective requires evidence of financial protection and appropriate completed care, alongside a credible means of financing the remaining resource requirements. Article details NeuralCipherai; Kadir Tamrak; Salih Yaldız; Feride Yaldız; Ömer Ağyol; Yavuz Selim Silay; Hasan Randa Quantitative methodological analysis with targeted narrative evidence Exact payment-cap identities and household cash-feasibility calculations distinguish clinical-fee protection from protection of the complete cash episode. Project: NeuralCipher. Bibliographic records are supplied in BibTeX and RIS formats for reference-management software, including Zotero. Reproducible calculations and figure data accompany the article. References Adams, J. L., Kangarloo, T., Tracey, B., O’Donnell, P., Volfson, D., Latzman, R. D., Zach, N., Alexander, R., Bergethon, P., Cosman, J., Anderson, D., Best, A., Severson, J., Kostrzebski, M. A., Auinger, P., Wilmot, P., Pohlson, Y., Waddell, E., Jensen-Roberts, S., . . . the Parkinson Study Group Watch-PD Study Investigators and Collaborators. (2023). Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study. npj Parkinson's Disease, 9(1), Article 64. https://doi.org/10.1038/s41531-023-00497-x Asaria, M., Griffin, S., Cookson, R., Whyte, S., & Tappenden, P. (2015). Distributional Cost‐Effectiveness Analysis of Health Care Programmes – A Methodological Case Study of the UK Bowel Cancer Screening Programme. Health Economics, 24(6), 742-754. https://doi.org/10.1002/hec.3058 Beck, C. A., Beran, D. B., Biglan, K. M., Boyd, C. M., Dorsey, E. R., Schmidt, P. N., Simone, R., Willis, A. W., Galifianakis, N. B., Katz, M., Tanner, C. M., Dodenhoff, K., Aldred, J., Carter, J., Fraser, A., Jimenez-Shahed, J., Hunter, C., Spindler, M., Reichwein, S., . . . Connect.Parkinson Investigators. (2017). National randomized controlled trial of virtual house calls for Parkinson disease. Neurology, 89(11), 1152–1161. https://doi.org/10.1212/WNL.0000000000004357 Bot, B. M., Suver, C., Neto, E. C., Kellen, M., Klein, A., Bare, C., Doerr, M., Pratap, A., Wilbanks, J., Dorsey, E. R., Friend, S. H., & Trister, A. D. (2016). The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data, 3(1), Article 160011. https://doi.org/10.1038/sdata.2016.11 Burq, M., Rainaldi, E., Ho, K. C., Chen, C., Bloem, B. R., Evers, L. J. W., Helmich, R. C., Myers, L., Marks, W. J., & Kapur, R. (2022). Virtual exam for Parkinson’s disease enables frequent and reliable remote measurements of motor function. npj Digital Medicine, 5(1), 65. https://doi.org/10.1038/s41746-022-00607-8 Canoro, V., Picillo, M., Cuoco, S., Pellecchia, M. T., Barone, P., & Erro, R. (2024). Development of the Digital Inclusion Questionnaire (DIQUEST) in Parkinson’s Disease. Neurological Sciences, 45(3), 1063-1069. https://doi.org/10.1007/s10072-023-07090-3 Canoro, V., Pilotto, A., Lena, F., Fioravanti, V., Longo, C., Schirinzi, T., Picillo, M., Pellecchia, M. T., Sorrentino, C., Cavallieri, F., Padovani, A., Malaguti, M. C., Modugno, N., Barone, P., & Erro, R. (2025). Digital Inclusion in Parkinson's Disease: A Case–Control Study. Movement Disorders Clinical Practice, 12(11), 1873-1881. https://doi.org/10.1002/mdc3.70171 Chaudhuri, K. R., Azulay, J. P., Odin, P., Lindvall, S., Domingos, J., Alobaidi, A., Kandukuri, P. L., Chaudhari, V. S., Parra, J. C., Yamazaki, T., Oddsdottir, J., Wright, J., & Martinez-Martin, P. (2024). Economic Burden of Parkinson’s Disease: A Multinational, Real-World, Cost-of-Illness Study. Drugs - Real World Outcomes, 11(1), 1-11. https://doi.org/10.1007/s40801-023-00410-1 Dorsey, E. R., Venkataraman, V., Grana, M. J., Bull, M. T., George, B. P., Boyd, C. M., Beck, C. A., Rajan, B., Seidmann, A., & Biglan, K. M. (2013). Randomized Controlled Clinical Trial of “Virtual House Calls” for Parkinson Disease. JAMA Neurology, 70(5), 565–570. https://doi.org/10.1001/jamaneurol.2013.123 Goh, Z. H. K., Cheong, J. L. Y., Marras, C., Tanner, C. M., Kasten, M., Korczyn, A. D., Chahine, L., Lo, R., Noyce, A. J., & on behalf of the Movement Disorders Society Epidemiology Study Group. (2022). Surveying Global Availability of Parkinson’s Disease Treatment. Journal of Parkinson’s Disease, 12(3), 1023-1034. https://doi.org/10.3233/JPD-213006 Gusovsky, A. V., Lin, C. C., Kerber, K., Reynolds, E. L., Callaghan, B. C., & Burke, J. F. (2024). Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications. Neurology, 103(10), e210029. https://doi.org/10.1212/WNL.0000000000210029 Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., Mauskopf, J., Mullins, C. D., Petrou, S., Pwu, R. F., Staniszewska, S., & CHEERS 2022 ISPOR Good Research Practices Task Force. (2022). Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. BMJ, 376, e067975. https://doi.org/10.1136/bmj-2021-067975 Kim, K., Song, S., Kim, S. S., Shin, D. H., & Lee, A. L. (2025). Economic value of AI-based MRI triage for Parkinson’s disease: a cost-benefit study in South Korea and the United States. Frontiers in Public Health, 13, 1723829. https://doi.org/10.3389/fpubh.2025.1723829 Maclagan, L. C., Emdin, A., Fu, L., Guan, J., de Oliveira, C., Marras, C., & Bronskill, S. E. (2025). Net Health System Costs of Parkinson Disease: A Propensity Score-Matched Health Administrative Data Cohort Study in Ontario, Canada. Neurology Clinical Practice, 15(1), e200371. https://doi.org/10.1212/CPJ.0000000000200371 Mokaya, J., Dotchin, C. L., Gray, W. K., Hooker, J., & Walker, R. W. (2016). The Accessibility of Parkinson's Disease Medication in Kenya: Results of a National Survey. Movement Disorders Clinical Practice, 3(4), 376-381. https://doi.org/10.1002/mdc3.12294 Pearson, C., Hartzman, A., Munevar, D., Feeney, M., Dolhun, R., Todaro, V., Rosenfeld, S., Willis, A., & Beck, J. C. (2023). Care access and utilization among medicare beneficiaries living with Parkinson’s disease. npj Parkinson's Disease, 9(1), 108. https://doi.org/10.1038/s41531-023-00523-y Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., Halliday, G., Goetz, C. G., Gasser, T., Dubois, B., Chan, P., Bloem, B. R., Adler, C. H., & Deuschl, G. (2015). MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 30(12), 1591–1601. https://doi.org/10.1002/mds.26424 Reynolds, E. L., Burke, J. F., Banerjee, M., Kerber, K. A., Skolarus, L. E., Magliocco, B., Esper, G. J., & Callaghan, B. C. (2020). Association of out-of-pocket costs on adherence to common neurologic medications. Neurology, 94(13), e1415-e1426. https://doi.org/10.1212/WNL.0000000000009039 Saiyed, M., Hill, A. J., Russell, T. G., Theodoros, D. G., & Scuffham, P. (2022). Cost analysis of home telerehabilitation for speech treatment in people with Parkinson’s disease. Journal of Telemedicine and Telecare, 28(7), 524-529. https://doi.org/10.1177/1357633X20948302 Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., Salomon, J. A., Sculpher, M. J., Trikalinos, T. A., Russell, L. B., Siegel, J. E., & Ganiats, T. G. (2016). Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA, 316(10), 1093–1103. https://doi.org/10.1001/jama.2016.12195 Skivington, K., Matthews, L., Simpson, S. A., Craig, P., Baird, J., Blazeby, J. M., Boyd, K. A., Craig, N., French, D. P., McIntosh, E., Petticrew, M., Rycroft-Malone, J., White, M., & Moore, L. (2021). A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ, 374, n2061. https://doi.org/10.1136/bmj.n2061 Sullivan, S. D., Mauskopf, J. A., Augustovski, F., Caro, J. J., Lee, K. M., Minchin, M., Orlewska, E., Penna, P., Rodriguez Barrios, J. M., & Shau, W. Y. (2014). Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Pract